Printer Friendly
The Free Library
14,815,393 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Prevention: New approach will test tenofovir for persons at high risk.


In a new approach to HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.  prevention, the Bill & Melinda Gates Melinda French Gates (born Melinda Ann French on August 15, 1964) is a former unit manager for several Microsoft products: Publisher, Microsoft Bob, Encarta, and Expedia. In 1994, she married Bill Gates, founder, chairman, and former chief software architect of Microsoft.  Foundation will fund a multinational trial of the antiretroviral drug “HAART” redirects here. For UK estate agency Haart, see Spicerhaart.

Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. Different classes of antiretroviral drugs act at different stages of the HIV life cycle.
 tenofovir, taken orally once daily by HIV negative persons at high risk, to see if it can prevent HIV infection. The study, by Family Health International, will take three years, and will focus on sexually active adults in countries with high HIV incidence. If it works, this method could be particularly important for women who cannot negotiate condom 1. condom - The protective plastic bag that accompanies 3.5-inch microfloppy diskettes. Rarely, also used of (paper) disk envelopes. Unlike the write protect tab, the condom (when left on) not only impedes the practice of SEX but has also been shown to have a high failure  use or other ways of protecting themselves.

Dr. Helene Gayle of the Bill & Melinda Gates Foundation noted that experience in using antiretrovirals to protect healthcare workers exposed to HIV, and infants exposed during childbirth, offered hope that it might be possible to prevent sexual transmission as well.

Comment

This study is important because it could open a new front in HIV prevention--and provide a woman-controlled protection method before microbicides or vaccines are available. Animal studies have suggested that the drug may prevent infection. And tenofovir, approved for over a year in the U.S. for use in HIV treatment, has fewer side effects Side effects

Effects of a proposed project on other parts of the firm.
 than other antiretrovirals, so it may be acceptable to persons at high risk but not already infected.
COPYRIGHT 2002 John S. James
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:James, John S.
Publication:AIDS Treatment News
Article Type:Brief Article
Geographic Code:1USA
Date:Nov 22, 2002
Words:199
Previous Article:Vaccine against three kinds of HIV begins human tests.(Brief Article)
Next Article:U.S. AIDS research needs tissue donations.
Topics:



Related Articles
Retroviruses Conference: Johns Hopkins Report.(Hopkins HIV Report)
Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26.
Tenofovir approved: Broad indication.(Brief Article)
More Uses for Tenofovir?
HIV medicine after Barcelona conference: interview with Howard Grossman, M.D.
After N-9, what next? Several potential microbicides are poised to be tested for effectiveness in humans.(nonoxynol-9)
Warning against Tenofovir+ddI+3TC, and "Triple Nuke" combinations.(Brief Article)
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread)--and warning on Viagra, Cialis, and Levitra.(Brief Article)
Lessons from two "triple nuke" failures (new training module).(Brief Article)
Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles